ANIP Q4 2025 Earnings — ANI Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

ANIPANI Pharmaceuticals, Inc.

$2B

Q4 2025 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$247M+29.6% YoY

Gross Profit

$238M96.2% margin

Operating Income

$48M19.5% margin

Net Income

$27M11.1% margin

EPS (Diluted)

$1.17

QoQ Revenue Growth

+8.4%

Cash Flow

Operating Cash Flow

$30M

Free Cash Flow

$7M

Stock-Based Comp.

$10M

Balance Sheet

Total Assets

$1.4B

Total Liabilities

$900M

Stockholders' Equity

$541M

Cash & Equivalents

$286M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$247M	$191M	+29.6%
Gross Profit	$238M	$110M	+115.4%
Operating Income	$48M	-$4M	+1200.4%
Net Income	$27M	-$10M	+367.5%

Revenue Segments

Sales of rare disease pharmaceutical products

$131M53%

Total Sales of Generics and Other

$103M42%

Sales of Established Brands

$12M5%